
 
 
 
 
 
 
 
 
  What is claimed is: 
 
 1. 
 A method for preparing a polypeptide using microorganism transformed by a gene encoding a fusion protein of the A-B type: 
 A-B (I) wherein A is a fusion partner comprises 25 or more amino acid residues comprising aspartic acid and glutamic acid residues in which total negative charges of the fusion partner exceeds 30%, and B is a target protein to be produced. 
 
 
 2. 
 The method for preparing a polypeptide according to claim 1, wherein part of the fusion partner A comprises a sequence of 7 consecutive amino acid residues with 5 or more negative charges. 
 
 
 3. 
 The method according to claim 1, wherein the fusion partner A is a peptide comprising MKIEEGKL at the amino terminus. 
 
 
 4. 
 The method for preparing a polypeptide according to claim 1, wherein the fusion peptide A is a peptide comprising one of a SEQ ID NO: 64 to 74 listed below. 
 SEQ ID NO: 64: MGSSHHHHHHSSGLVPRGSDMAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 65: MAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 66: MKffiEGKLAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 67: MSEQHAQGAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 68: MKJEEGKLAGDNDDLDLEEALEPDME SEQ ID NO: 69: MSEQHAQGAGDNDDLDLEEALEPDME 
 SEQ ID NO: 70: MKTEEGKLEALEPDMEEDDDQ 
 SEQ ID NO: 71: MSEQHAQGEALEPDMEEDDDQ 
 SEQ ID NO: 72: MKIEEGKLAGDNDDLDLEEAL 
 SEQ ID NO: 73: MSEQHAQGAGDNDDLDLEEAL SEQ ID NO: 74: MGSSHHHHHHSSAGDNDDLDLEEALEPDMEEDDDQ   
 
 
 5. 
 The method for preparing a proinsulin or its analogues according to one of claims l to 4.  
 
 
 6. 
 The method for preparing insulin, by further comprising the process of enzymatic or chemical cleavage after producing the proinsulin or its analogues according to claim 5.  
 
 
 7. 
 A pharmaceutical composition of insulin prepared according to claim 6 and pharmaceutically acceptable carrier. 
 
 
 8. 
 A method for preparing a Granulocyte colony stimulating factor (GCSF), or its analogues according to claims 1 to 4. 
 
 
 9. 
 A pharmaceutical composition of the GCSF prepared according to claim 8 and pharmaceutically acceptable carrier. 
 
 
 10. 
 A method for preparing a Growth hormone (GH) or its analogues according to claims lto 4. 
 
 
 11. A pharmaceutical composition of the GH prepared according to claim 10 and pharmaceutically acceptable carrier . 
 
 
 12. A method for preparing a Bone morphogenetic protein(BMP)-2 or its analogues according to claims lto 4. 
 
 
 13. 
 A pharmaceutical composition of the BMP-2 prepared according to claim 12 and pharmaceutically acceptable carrier.   
 
 
 14. 
 The method for preparing a polypeptide according to claims 1 to 4, wherein the method further comprises obtaining the target protein from the fusion protein by incorporating enzymatic or chemical cleavage site to the carboxyl-terminus of the fusion partner. 
 
 
 15. 
 A fusion protein of A-B type; A-B (I) wherein A is a fusion partner comprising 25 or more amino acid residues comprising aspartic acid and glutamic acid residues in which total negative charges of the fusion partner exceeds 30%, and B is a target protein to be produced. 
 
 
 16. 
 The fusion protein according to claim 15, wherein the fusion partner A is a peptide comprising a sequence of 7 consecutive amino acid residues with 5 or more negative charges; 
 
 
 17. 
 The fusion protein according to claim 16, wherein the fusion partner A is a peptide comprising MKIEEGKL at the amino terminus. 
 
 
 18. The fusion protein according to claim 17, wherein the fusion peptide A is a peptide comprising one of a SEQ ID NO: 64~74 listed below. 
 SEQ ID NO: 64: 
 MGSSHHHHHHSSGLVPRGSDMAGDNDDLDLEEALEPDMEEDDDQ SEQ ID NO: 65: MAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 66: MKTEEGKLAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 67: MSEQHAQGAGDNDDLDLEEALEPDMEEDDDQ 
 SEQ ID NO: 68: MKTEEGKLAGDNDDLDLEEALEPDME 
 SEQ ID NO: 69: MSEQHAQGAGDNDDLDLEEALEPDME SEQ ID NO: 70: MKTEEGKLEALEPDMEEDDDQ  SEQ ID NO: 71: MSEQHAQGEALEPDMEEDDDQ 
 SEQ ID NO: 72: MKIEEGKLAGDNDDLDLEEAL 
 SEQ ID NO: 73: MSEQHAQGAGDNDDLDLEEAL 
 SEQ ID NO: 74: MGSSHHHHHHSSAGDNDDLDLEEALEPDMEEDDDQ 
 
 
 19. 
 The fusion protein according to claim 15, wherein the target protein B is a Proinsulin, a Growth Hormone, a Granulocyte colony stimulating factor, or a Bone morphogenetic protein -2. 
 
 
 20. 
 The fusion protein according to claim 19, wherein the proinsulin is converted to insulin by enzymatic or chemical cleavage. 
 
 
 21. 
 An expression vector which comprises a gene encoding a fusion protein of A-B type wherein the fusion partner A is Px and the target protein B is a Proinsulin, a Growth Hormone, a Granulocyte colony stimulating factor, or a Bone morphogenetic protein -2; wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11. 
 
 
 22. 
 A microorganism transformed with the expression vector in claim 21. 
 
 
 23. The microorganism according to claim 22, wherein the microorganism is E. coli 
 BL21 (DE3), HMS174 (DEi) or Rosetta (DE3). 
 
 
 24. 
 The microorganism according to claim 23, wherein the microorganism is E. coli Rosetta (DE3) (Accession number KCCM 10684P).  
 
 
 
 
 
 
 
 
 
 
